Bristol-Myers v. Biocraft
Executive Summary
Bristol-Myers received a preliminary injunction prohibiting Biocraft from marketing its generic cefadroxil antibiotic on Feb. 28, Bristol announced in a same-day release. Newark Federal Court Judge Dickenson Debevoise determined that the generic product would infringe on Bristol-Myers' crystalline cefadroxil monohydrate patent, due to expire in 2002. Bristol-Myers is seeking a full trial in order to obtain a permanent injunction. Biocraft has 90 days to appeal the ruling to the U.S. Court of Appeals.
You may also be interested in...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: